Kornimate/medical-research-clean huggingface dataset:
prospective trial comparing response to hyperbaric oxygen treatment in patients with interstitial cystitis

Conditions: Interstitial Cystitis

Summary: to review the results of hyperbaric oxygen therapy (hbot) on the symptoms of interstitial cystitis (ic). to determine if there is greater symptom improvement in the ulcerative vs the non-ulcerative patients with interstitial cystitis.

there are multiple published studies outside of the united states on hbot for treatment of interstitial cystitis. none of these studies compares ulcerative ic and non-ulcerative ic.

Eligibility criteria:
inclusion criteria: * interstitial cystitis. * urinary frequency of at least 8 times per 24 hours period. * patients with ulcerative ic must have undergone previous biopsy negative for cancer. * patients must agree to not begin any additional treatment for ic until study completion. exclusion criteria: * absolute or relative contraindication to hyperbaric oxygen treatment. * patients dependent on intermittent catheterization or indwelling catheter to empty bladder. * any imminent change in residence, which could compromise compliance. * unlikely to be compliant due to unmanaged medical or psychological problems. * severe debilitating concurrent medical conditions. * a history of pelvic radiation, bladder stone, bladder cancer or cancer in situ, or urethral cancer. * precious bladder or neurologic surgery which has affected bladder function. * currently has an active urethral stone, ureteral stone or urethral diverticulum. * subject misses more than 10 treatments. * severe claustrophobia.

Keywords: interstitial cystitis
comparison of two application techniques for let gel

Conditions: Lacerations; Pain, Procedural; LET

Summary: comparison of anesthetic efficacy of lidocaine (4%), epinephrine (0.1%), and tetracaine (0.5%) topical gel (let) applied three times for 10 minutes each time vs. once for 30 minutes prior to suturing simple lacerations in children aged 7-17 years.

randomized single-blinded clinical trial with convenience sampling of the anesthetic efficacy of a single 30-minute application vs three 10-minute applications of lidocaine (4%), epinephrine (0.1%), and tetracaine (0.5%) topical gel (let) prior to suturing simple lacerations in children aged 7-17 years seen in the emergency department.

Eligibility criteria:
inclusion criteria: * simple \<= 3cm lacerations requiring suturing (as decided by clinician care providers) * plan to suture with simple interrupted sutures exclusion criteria: * lacerations involving the hands, feet, genitals, tongue, mucus membranes, nose, ears, or occurring over joints * patients whose primary language was neither english nor spanish * developmentally delayed or disabled patient such that they were unable to give a pain score * patients requiring procedural sedation or anxiolysis with oral or intranasal midazolam
efficacy of intraoperative magnesium sulphate vs dexmedetomidine on emergence agitation in pediatric patients

Conditions: Magnesium Sulphate; Dexmedetomidine; Emergence Agitation; Pediatric Patients

Summary: this study aimed to compare the effectiveness of intraoperative magnesium sulfate versus dexmedetomidine infusions on emergence agitation that follows anesthesia using sevoflurane immediately and after 30 min in the post-anesthesia care unit (pacu), regarding pediatric anesthesia emergence delirium scale (paed), richmond agitation sedation scale (rass), and hemodynamics

emergence agitation (ea) is a postoperative phenomenon that occurs in children after sevoflurane anesthesia, with an occurrence rate of up to 80%. dexmedetomidine acts on α-2 adrenergic receptors, producing sedation and hypnosis with anxiolytic effects, without a clinically significant depressive impact on heart rate, blood pressure, and respiratory rate, complementing an earlier study suggesting the possible effective and safe use of dexmedetomidine as a part of anesthesia care to prevent emergence agitation in children. magnesium sulfate also has been reported to decrease the incidence and severity of emergence agitation and the need for postoperative rescue doses of analgesia in children, and its use was not associated with increased postoperative side effects or delayed recovery.

Eligibility criteria:
inclusion criteria: * age from 4 to 8 years old. * both sexes. * patients american society of anesthesiologists (asa) physical status i to ii. * duration of surgery: not exceeding two hours exclusion criteria: * legal guardian refusal. * neurological abnormalities, such as cerebral palsy. * any physical and/or developmental challenge. * patients on sedatives, anticonvulsants, or any medications that may alter conscious level in children. * coexisting renal or cardiovascular diseases.
this is a study evaluating the efficacy and safety of ltg-001 for acute pain after surgical removal of impacted third molars

Conditions: Acute Pain, Postoperative

Summary: the goal of this clinical trial is to learn if ltg-001 works to treat pain after third molar removal surgery in adults. it will also learn about the safety of ltg-001. the main questions it aims to answer are: does drug ltg-001 treat the acute pain after surgical removal of impacted third molars (wisdom teeth) over 12 hours? how tolerable is ltg-001 after surgical removal of impacted third molars (wisdom teeth) over 12 hours? researchers in part 1 will compare drug ltg-001 to a placebo (a look-alike substance that contains no drug) and in part 2 to a placebo and a comparator to see if drug ltg-001 treats the post-surgical pain. participants will: take ltg-001 one time after the surgical removal of impacted third molars. remain at the clinic for 12 hours after study dosing and return after a week for a safety check up. report the pain relief during the 12 hours after dosing to record changes in the post-operative pain


Eligibility criteria:
inclusion criteria: * subject is male or female aged 18 to 50 years, inclusive, at the time of signing the informed consent * has a body weight ≥ 45 kg and a bmi ≤ 35 kg/m2. * subject requires extraction of 2 or more third molars, two of which must be mandibular molars that must be fully or partially bony, or combination of one fully and one partially bony impaction. * subject must agree to study required use of birth control. * post-surgical pain must meet protocol requirements. exclusion criteria: * inability to take oral medications * prior dental surgery within 60 days or other surgical history that could confound surgery or post-operative procedures. * history of impaired hepatic function or heart disease. * abnormal liver laboratories or other lab abnormality indicative of serious medical condition. * sensory abnormality that would confound post-surgery pain assessments. * chronic use of nsaids, benzodiazepines, opioid use within the last year, use of medications that prolong qtc intervals, or other dietary and medication restrictions. * a subject with sleep apnea and/or on a home continuous positive airway pressure machine. * positive drug screen. * participant is under legal custodianship.

Keywords: acute pain surgical removal of impacted third molars wisdom teeth
comparison of anti-inflammatory effects of seroflo and seretide in patients with asthma

Conditions: Asthma

Summary: the purpose of this study is to test hypothesis if sereflo (ics/laba) could reduce airway inflammation in asthmatic patients in the same as seretide.


Eligibility criteria:
inclusion criteria: * age between 20-80 years * patients with asthma diagnosed by according to the american thoracic society criteria * a baseline fev1 \> or = 50% predicted with a reversibility of fev1 after therapy with inhaled salbuterol (2.5 mg) of fev1 12% or with provocative concentration of a methacholine causing a 20% fall in fev1 (pc20) of \< or = 8 mg/ml * prescribed use of inhaled corticosteroids (any brand) for at least 12 weeks prior to study entry * the daily prescribed dose of inhaled corticosteroids during the last 4 weeks prior to study entry should have been constant and at least 250 μg/day of fluticasone at least 400 μg/day of budesonide at least 500 μg/day of any other beclomethasone * be able to provide written informed consent exclusion criteria: * any asthma exacerbation or respiratory tract infection affecting asthma within 4 weeks prior to the randomization visit * intake of oral, parenteral corticosteroids within 4 weeks and/or depot parenteral corticosteroid within 12 weeks prior to the randomization visits * current or previous smoker with a smoking history of \> or = 10 pack years * previous randomization of treatment in the present study * known or suspected hypersensitivity to study therapy * use of any β-blocking agent, including eye-drops * pregnancy, breast-feeding or planned pregnancy during the study. fertile women not using acceptable contraceptive pill measures

Keywords: asthma
concurrent treatment of substance abuse and child maltreatment

Conditions: Substance Use; Child Maltreatment

Summary: the co-occurrence of child maltreatment and parental substance-use problems is a major public health problem with serious consequences for children, parents, families, and the community at large. the need for effective dual treatment of caregiver substance abuse and child maltreatment is unquestionable, but there is a dearth of controlled treatment outcome studies with substance-using parents who have engaged in child maltreatment. this project examines two evidence-based treatments-contingency management for substance-use problems and pathways triple p parenting intervention to improve parenting for prevention of child-maltreatment recurrence. these two systematic interventions are being tested in the context of traditional outpatient treatment for substance-use problems.


Eligibility criteria:
inclusion criteria: * open child protective services case for child maltreatment * beginning intensive outpatient treatment for drug or alcohol use problem * at least one child 2-8 years of age exclusion criteria: * not primary custodial parent for child 2-8 years of age * serious mental illness * residing outside the two participating counties

Keywords: child welfare system parental substance use problem child maltreatment parenting
early detection of at-risk septic patients

Conditions: Sepsis

Summary: the purpose of this study is to determine whether additional investigations used in other parts of healthcare can be used in the emergency department to identify critically ill patients quicker than usual care.

the investigators intend to recruit 56 patients with suspected sepsis who attend the emergency department. the investigators want to use a device to monitor tissue oxygen levels when they first come into the emergency department as well as the change in tissue oxygen levels when a tourniquet is applied for 3 minutes. the investigators will take novel blood tests when the patient is having their routine bloods. finally, the investigators will use a special camera to take specialised pictures of the small blood vessels under the tongue which will show blood flow through these vessels. the investigators will follow the recruited patients and determine if our extra data is better at determining who needs critical care. a significant proportion of patients may be too unwell or too distressed to consent to be part of this study. at the earliest opportunity, the investigators will ask patients when they have been stabilised and are able to give consent. if they say no, they will be removed from the study and their care will not be affected by this decision. the results could help us identify septic shock as early as possible so that these unwell patients are identified early and get the correct treatment they need. this could mean starting advanced treatments usually found in the intensive care unit very early on in a patient's journey.

Eligibility criteria:
inclusion criteria: 1. differential diagnosis which includes infection 2. change in the quick sequential organ failure assessment (qsofa) ≥2 or national early warning score 2 (news2) score ≥5 3. aged ≥18 years exclusion criteria: 1. traumatic injury 2. rockwood frailty score ≥6 3. critical care therapy previously believed to not be in patient's best interests 4. critical care therapies-initiated pre-hospital. critical care therapies defined as: 4.1 mechanical ventilation 4.2 vasopressor/inotrope therapy 4.3 sedation or a general anaesthetic 4.4 pre-hospital transfusion of blood products 4.5 extra-corporeal support 5. advanced directive refusing critical care therapies. 6. acute cardiac failure 7. active gastrointestinal bleed 8. massive pulmonary embolism 9. icu admission declined by critical care team 10. treated in an acute hospital \<6 hours before presentation to the emergency department
group psychotherapy for adolescents with substance use

Conditions: Substance Abuse

Summary: background: substance abuse among children and adolescents is an important public health issue in taiwan. kaoshiung chang gung memorial hospital and taiwan kaoshiung juvenile and family court will cooperate in a counseling program for adolescents with illicit drug abusers in 2013, to perform a mandatory 10-week family-based group psychotherapy. aims: this study aims (1) to investigate the effectiveness of the family-based group psychotherapy for adolescents with illicit drug abusers and their parents; (2) to identify whether the counseling program is effective for preventing the adolescents from relapse of substance abuse. expected results: the investigators expect that (1) group psychotherapy may involve comprehensive benefits for adolescents with illicit drug abusers, by improving the changes in adolescents' substance-craving symptoms and behavioral problems, and reducing stress of their parents; (2) this counseling program is effective for preventing the adolescents from relapse of substance abuse; (3) the findings in this study will not only demonstrate empirical evidence of treatment effectiveness for adolescents with illicit drug abuse, but will also provide useful clues for future implementation of policy making.

1. the investigators plan to recruit 200 adolescents (=\< 20 years) with illicit drug abusers and their parents (100 of intervention group and 100 of comparison group). 2. the intervention group consists of youths that participate in a program that combines a weekly 10-session out-patient motivational enhancement psychotherapy (mep) program for youths with an additional weekly 10-session parenting skill training (pst) program for their guardians. 3. the comparison group consists of youths that receive standard supervision by the court. all participants were followed up for a maximum of three years. 4. the assessments for adolescents and their parents will be taken at pre- and post-treatment, using the adolescents' behavior-problem scale, the craving beliefs questionnaire, the family apgar, the parenting stress index-short from (psi/sf) and the chinese health questionnaire (chq). 5. the information of adolescents' relapse of substance abuse will be collected by kaoshiung juvenile and family court.

Eligibility criteria:
inclusion criteria: * the adolescents with illicit drug age between 12 to 20. * one of their parents can attend the counseling program. exclusion criteria: * the adolescents or their parents can't attend the program.

Keywords: substance abuse group psychotherapy family therapy longitudinal study child and adolescent
impact of preoperative opioid-free multimodal analgesia on time to trial of void in ambulatory urogynecologic surgeries

Conditions: Pain, Postoperative; Postoperative Pain, Acute

Summary: this is a double-arm randomized control trial evaluating the impact of preoperative opioid-free analgesia on time to trial of void in ambulatory urogynecologic surgeries. the investigators hypothesize that receipt of acetaminophen, celecoxib and gabapentin preoperatively versus acetaminophen alone will reduce the time to trial of void in patients undergoing same-day minor urogynecologic procedures.


Eligibility criteria:
inclusion criteria: 1. provision of signed and dated informed consent form 2. stated willingness to comply with all study procedures and availability for the duration of the study 3. all female patients over 18 years of age from the northwell health urogynecology offices in bay shore, syosset, and huntington, ny who are undergoing transvaginal minor urogynecologic surgery (midurethral sling, periurethral bulking injections, anterior repair, posterior repair, and perineorrhaphy) at south shore surgery center 4. in good general health as evidenced by medical history 5. ability to take oral medication and be willing to adhere to the study intervention 6. patients may be english or spanish-speaking and must be able to provide informed consent exclusion criteria: 1. pregnancy or lactation 2. younger than age 18 3. known allergic reactions to acetaminophen, celecoxib or gabapentin or any components within the medication formulation 4. patients with myasthenia gravis, renal disease with crcl \< 50, seizure disorder, substance use disorder, anaphylaxis and angioedema to gabapentin, drug reaction with eosinophilia and systemic symptoms (dress), driving impairment, increased seizures suicidal behavior and respiratory depression. 5. patients with a , history of asthma, urticaria, or other allergic type reactions after taking aspirin or other nsaids or dress, history of gastric bypass surgery, heart failure, active gi ulcer, active gi bleeding, inflammatory bowel disease, cerebrovascular bleeding, liver impairment/hepatic disease, hyperkalemia. 6. patients with compromised renal function who are notable to receive nsaids 7. patients with significant cardiovascular disease, such as patients with heart failure 8. patient with recent evidence of worsening fluid retention 9. both non-english and non-spanish speaking patients 10. urogynecologic surgeries for apical repair (sacrocolpopexy, uterosacral ligament suspension, sacrospinous ligament suspension, colpocleisis) 11. current use of illicit substances (cocaine, non-prescription opioids, marijuana) 12. current use of gabapentin as home medication
assessment of leflunomide efficacy and hepatotoxicity in patients with rheumatoid arthritis through pharmacokinetic and genetic approaches

Conditions: Rheumatoid Arthritis

Summary: the ra patients receiving leflunomide for more than one month, and not receiving other dmards (except hydroxychloroquine), will be enrolled to assess their disease activity. blood samples will be collected for genetic studies and pharmacokinetic assay of the blood levels of the drug and its active metabolite.


Eligibility criteria:
inclusion criteria: * rheumatoid arthritis patients already receiving leflunomide with or without hydroxychloroquine but without other disease modifying agents exclusion criteria: * those diagnosed with other rheumatic diseases or rheumatoid patients receiving disease modifying agents other than leflunomide
the prophylactic effect of garlic tablets to prevent nosocomial infections in intensive care unit patients.

Conditions: Nosocomial Infection

Summary: the goal of this clinical trial is to learn if garlic tablets works to prevent nosocomial infections in hospitalized patients in icu. the main questions it aims to answer are: does garlic tablets administration lower the occurence of nosocomial infections in hospitalized patients in icu?


Eligibility criteria:
inclusion criteria: * all patients aged from 18 to 65 years old admitted to intensive care units without any type of infection. exclusion criteria: 1. patients with signs /symptoms of infection. 2. patients with human immunodeficiency virus, malignancy and patients with a history of recent immunosuppressants or corticosteroids administration. 3. patients with bleeding disorders or abnormal coagulation profile 4. patients who will planned for surgery within 2 weeks.

Keywords: nosocmial infection prophylaxis garlic
a study of the long-term safety and efficacy of adalimumab in subjects with intermediate-, posterior-, or pan-uveitis

Conditions: Uveitis

Summary: the purpose of this study is to evaluate the long term efficacy and safety of adalimumab participants with non-infectious intermediate-, posterior- or pan-uveitis.

this study was initially planned to run for 78 weeks but was extended for ethical reasons, to avoid leaving participants untreated who had responded well to adalimumab treatment, so that participants were allowed to remain in the study until regulatory and/or reimbursement approval for the treatment of uveitis in adults was obtained for their respective countries. data were collected through week 366 (maximum), but because of decreasing sample size that became too small toward the end of the study to allow for meaningful conclusion, data cut off for efficacy analyses (intent to treat \[itt\] population) occurred at week 246, as less than 10% of participants in the itt set had visits beyond this timepoint.

Eligibility criteria:
inclusion criteria: * participant must have successfully enrolled in either study m10-877 or m10-880 and either met the endpoint of "treatment failure" or completed the study exclusion criteria: * a participant will be excluded from this study if the participant discontinued from study m10-877 or m10-880 for any reasons other than having a treatment failure event * participant with corneal or lens opacity that precludes visualization of the fundus or that likely requires cataract surgery during the duration of the trial * participants with intraocular pressure of \>= 25 mmhg and on \>= 2 glaucoma medications or evidence of glaucomatous optic nerve injury * participant with proliferative or severe non-proliferative diabetic retinopathy or clinically significant macular edema due to diabetic retinopathy * participant with neovascular/wet age-related macular degeneration * participant with abnormality of vitreo-retinal interface (i.e., vitreomacular traction, epiretinal membranes, etc.) with the potential for macular structural damage independent of the inflammatory process * participant with a systemic inflammatory disease that requires therapy with a prohibited immunosuppressive agent at the time of study entry

Keywords: intermediate-uveitis non-infectious uveitis posterior-uveitis active uveitis pan-uveitis uveitis